Navigation Links
New research shows ACTOS is associated with a 38 percent lower risk of heart attack
Date:9/22/2007

Amsterdam, The Netherlands, Sept. 19, 2007 -- New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS (pioglitazone HCI) and its benefits regarding improved blood glucose and blood lipid levels for patients with type 2 diabetes. The unique outcomes, including some clinical practice results, reinforce the consistency of pioglitazone data and underscore that ACTOS has different effects from the other thiazolidinedione rosiglitazone due to differences in molecular structure.

New research [1] presented at EASD has shown that therapies which include pioglitazone are associated with significant reductions in the risk of stroke or myocardial infarction (MI) compared to non-thiazolidinedione therapies. This retrospective analysis of case records from a large managed care database of diabetes patients have shown that the adjusted relative risk of stroke for the pioglitazone group was 20 percent lower than the group not receiving pioglitazone. Likewise, the risk of heart attack over the study period was 38 percent lower in patients receiving pioglitazone than in those taking an anti-diabetes drug regimen that did not include pioglitazone. John Betteridge, Professor of Endocrinology and Metabolism at University College, London said: The results of this analysis are very welcome and support the findings from the PROactive study of pioglitazone for secondary prevention of vascular events which showed a reduction in stroke and heart attack in this high risk population.

In addition, the GLAI study [2] , also presented at EASD, further reflects the cardioprotective strength of pioglitazone. A new analysis of data from the first three months of this six-month head-to-head study of pioglitazone and rosiglitazone, in which the endpoint was the change in serum lipids, demonstrated that initial treatment with a starting dos
'/>"/>

Contact: Alison Wright
alison.wright@ketchum.com
44-207-611-3662
Ketchum
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Stem cell research- now Nobel Laureates join the debate
3. Researchers urge caution in using ear tube surgery
4. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
5. Spouses and other partners lower blood pressure says new research
6. Researchers Scale to assess the Severity of Epilepsy in Kids
7. More Research Required For COPD
8. Researchers identify the early makers of Neonatal Sepsis
9. OHSU Researchers Announce New Discovery
10. Skin Cancer Research To Go Global
11. Researchers Identify Gene Connected To Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Gray HealthDay Reporter , , TUESDAY, May 21 ... was once next to impossible, but a new study ... screening with low-dose CT scans may help spot the ... patients considered at the greatest risk for lung cancer, ... getting CT scans and follow-up biopsies to confirm the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Pathways ... who are grieving to remember and honor a loved ... of Remembrance Memorial Service, Sunday, June 2, 2013, 3-4 ... Boulevard, San Mateo, CA 94402. , The Pathways ... includes a short program with music, readings and support. ...
(Date:5/21/2013)... 2013 Not all treatments are effective ... Borderline Personality Disorder (BPD) and addiction. Dialectical Behavior Therapy ... successful for the treatment of both BPD and substance ... Ph.D., clinical director of Clearview Women’s Center for ... provide attendees of the West Coast Symposium on Addictive ...
(Date:5/21/2013)... obese patients are significantly more likely than their ... a practice that disrupts continuity of care and ... Hopkins research suggests. , The practice of "doctor ... of negative experiences with the health care system, ... unsolicited weight loss advice by providers, or improperly ...
(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
Breaking Medicine News(10 mins):Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 2Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 3Health News:Hospice Offers Evening of Remembrance Memorial Service in San Mateo, California 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2
... dedicated to the health and well being of children, ... (FDA) has approved an investigational new drug application; ... topical solution for the treatment of head lice. ... professionals a new choice for the treatment of head ...
... cyclists will be participating in the Memory Ride for Alzheimer's ... to fight the disease that affects more than 5 ... 11th annual Memory Ride has a personal story to tell ... who has struggled with the disease. ,The Alzheimer's ...
... is not as squeaky-clean as she appears . ,In a ... she is quite the opposite of her supposed righteous image. ... Do you think you have a squeaky-clean image? Im like, Could ... Us Weekly quoted her, as telling the mag. ,I ...
... the University of Idaho is helping to increase understanding ... identify conditions that make women prone to infections and ... problems. ,Women suffer from insidious health problems, ... send them in droves to seek medical treatment, said ...
... the occurrence of anaphylaxis between the northern and southern ... be fatal without treatment with epinephrine. The striking ... risk, currently are without explanation. The investigators hypothesize, however, ... sunshine, may play a role and that this hypothesis ...
... can relieve people of shyness, and help them socialise with ... use, and an individual can boost self-confidence just by squirting ... that the spray harnesses the powers of a feel-good hormone ... in social recognition and bonding. ,The mammalian ...
Cached Medicine News:Health News:Vaginal Bacteria Vary Among Healthy Women 2Health News:Large Geographic Differences in EpiPen Prescriptions in the U. S. 2
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... 21, 2013  BioRestorative Therapies, Inc. ("BRT" or the ... on developing stem cell based therapies for various personal ... its President and CEO, will be presenting at the ... be held on Thursday, May 30, 2013 at the ... in New York City.  Mr. Weinreb,s presentation will take ...
(Date:5/21/2013)... and HENDERSONVILLE, N.C. , ... bidding procurement program for home medical equipment is ... North Carolina to lay off employees or ... quality of service and products received by Medicare beneficiaries, ... the defective and dangerous program, the Centers for ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 2North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 4
... ABBOTT PARK, Ill., Nov. 12 Nearly one in three ... and nearly 34 million have low HDL "good" cholesterol levels. ... and trigs, Abbott has launched two Web sites: ... "Unhealthy high triglyceride and low HDL levels are factors that ...
... IRVINE, Calif., Nov. 12 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, and CareFusion ... device company, today announced a multi-year technology licensing ... capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology ...
Cached Medicine Technology:New Web Sites Educate About Triglycerides and HDL Cholesterol 2CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 2CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 3CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 4
Double-ended. Blades set at 45 and 90 degrees. Hexagonal handle....
5 mm curved blade. Round handle....
2 mm x 3 mm tapered blade. Referred to as "Number Two Knife". Angled 45 degrees. Round handle....
7 mm strong curved blade. Round handle....
Medicine Products: